Korro Bio's change in working capital for the quarter that ended in Jun. 2023 was $-0.86 Mil.
Korro Bio's change in working capital for the fiscal year that ended in Dec. 2023 was $4.28 Mil.
It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).
Korro Bio Change In Working Capital Historical Data
The historical data trend for Korro Bio's Change In Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Korro Bio Change In Working Capital Chart
Korro Bio Annual Data
Trend
Dec21
Dec22
Dec23
Change In Working Capital
0.90
-0.63
4.28
Korro Bio Semi-Annual Data
Dec21
Jun22
Dec22
Jun23
Dec23
Change In Working Capital
-
-0.19
-0.44
-0.86
5.15
Korro Bio Change In Working Capital Calculation
Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $4.28 Mil.
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.
Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net
(566)
(614)
(796)
Inventories
(1,667)
(2,759)
(3,727)
Accounts payable
531
1,061
2,687
Accrued liabilities
103
271
(935)
Accrued income taxes
(1,224)
981
994
For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Korro Bio Change In Working Capital Related Terms
Thank you for viewing the detailed overview of Korro Bio's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KRRO has been successfully added to your